



Department of Consumer Affairs
Business Services Office - Contracts
1625 N. Market Blvd., Suite S-103
Sacramento, CA 95834



IFB DCA-26-01 DRUG TESTING SERVICES

Question and Answers #1

May 7, 2026

To: Prospective Bidders

Subject: Questions and Answers #1 DCA-26-01

This will serve to inform all prospective bidders of Question and Answers 1 for DCA-26-01 entitled "DRUG TESTING SERVICES"

This Questions and Answers responds to the questions received from prospective bidders.

Question #1: Cost Sheets, Pages 11-100, "The cost for the Base Panel Drug Screening for urine, hair, oral and blood shall be based on Exhibit A, Attachment I": Can DCA please confirm that the base panels are the same for all boards?

Answer #1: Yes All boards will utilize the listed panels as stated.

Question #2: Cost Sheets, Pages 11-100, "The collection site fee shall include, but is not limited to all administrative, set up, processing, laboratory, shipping, and chain of custody forms": Regarding the item for "Collection Site Fee" on the cost sheets, is the intent that this is a single fee to be applied to all collections independent of the site used, a Tiered collection model with multiple Tiers, or an average of variable collection costs? Each test type is listed for a cost.

Answer #2: For purposes of the cost sheets, the "Collection Site Fee" is interpreted as an average of variable collection costs. This average reflects the blended expenses associated with administrative activities, setup, processing, laboratory handling, shipping, and chain-of-custody requirements across the full mix of test types included in the scope. Because each test type carries different operational demands and cost drivers, the fee is assumed to represent the weighted average cost based on anticipated volumes rather than a single fixed fee or a tiered collection model.

Question #3: Cost Sheets, Pages 11-100: Could DCA please clarify the method used to determine the estimated number of tests for the "Collection Site Fee"? Specifically, could you provide additional detail regarding the 1,950 tests identified for Collection Site Fees in the Dental Hygiene Board of California cost sheet (page 26), given the Board's relatively low testing volume.

Answer #3: The Board confirmed these are the numbers they provided for the intent of the solicitation. As stated on the IFB:

"The number of tests shown is only an estimate, used for determining the low bidder, and is not binding on the contracting agency. However, the actual costs quoted above by the bidder shall be binding for the term of the Agreement. Where the number of tests is estimated at zero, the associated costs entered by the contractor shall still be binding during the term of the agreement if those tests are used."

Questions and Answers #1

DCA-26-01

Page 2

Question #4: Cost Sheets, Page 28: Could DCA confirm the estimated number of urine tests for the Medical Board of California is “1,5000” as documented, or is it possible this number should be “1,500”?

Answer #4: Confirmed: 15,000

Question #5: TACPA, Page 10, Attachment 10: Is the Target Area Contract Preference Act (TACPA) applicable to this contract, in addition to Small Business Preference—i.e. if applicable, 5% SB preference plus 5% TAPCA preference to equal a 10% overall preference?

Answer #5: DGS evaluates all TACPA applications and ensures compliance with the program's requirements. If TACPA is applicable, the determined percentage for TACPA preference based on information provided on sections I and II of the TACPA form ST 830 submitted by the vendor. The percentage is determined by Department of General Services (DGS) Dispute Resolution Unit and Preference Programs (DRU). TACPA is applied regionally and not necessarily statewide. If SB preference were given, and TACPA were given; they would be in total percentage.

Question #6: Time Schedule, Page 4: Can DCA confirm that all times provided are Pacific Time (PT)?

Answer #6: Yes Pacific Standard Time.